Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTL NYSE:CO NASDAQ:LXEO NASDAQ:MRAI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.63+2.5%$1.48$1.18▼$2.70$433.81M1.931.44 million shs1.48 million shsCOGlobal Cord Blood$0.95$0.99$2.03▼$5.50$115.47M0.16216,519 shs136 shsLXEOLexeo Therapeutics$5.09-7.5%$6.09$2.51▼$10.99$399.68M1.52712,701 shs787,385 shsMRAIMarpai$0.29-5.3%$0.34$0.22▼$1.78$7.35M4.3853,335 shs20,903 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics0.00%+3.82%+1.24%+16.43%+33.61%COGlobal Cord Blood0.00%0.00%0.00%0.00%-9.52%LXEOLexeo Therapeutics0.00%-12.69%-22.64%-19.33%+89.22%MRAIMarpai0.00%+7.52%+11.70%-29.20%-78.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.63+2.5%$1.48$1.18▼$2.70$433.81M1.931.44 million shs1.48 million shsCOGlobal Cord Blood$0.95$0.99$2.03▼$5.50$115.47M0.16216,519 shs136 shsLXEOLexeo Therapeutics$5.09-7.5%$6.09$2.51▼$10.99$399.68M1.52712,701 shs787,385 shsMRAIMarpai$0.29-5.3%$0.34$0.22▼$1.78$7.35M4.3853,335 shs20,903 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics0.00%+3.82%+1.24%+16.43%+33.61%COGlobal Cord Blood0.00%0.00%0.00%0.00%-9.52%LXEOLexeo Therapeutics0.00%-12.69%-22.64%-19.33%+89.22%MRAIMarpai0.00%+7.52%+11.70%-29.20%-78.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 2.89Moderate Buy$8.75436.81% UpsideCOGlobal Cord Blood 0.00N/AN/AN/ALXEOLexeo Therapeutics 2.89Moderate Buy$18.88270.83% UpsideMRAIMarpai 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CO, MRAI, LXEO, and AUTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/14/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026AUTLAutolus Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.005/11/2026LXEOLexeo Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.005/1/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/29/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026AUTLAutolus Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/17/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026AUTLAutolus Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/31/2026AUTLAutolus Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$12.00 ➝ $10.003/27/2026AUTLAutolus Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$92.62M4.68N/AN/A$0.67 per share2.43COGlobal Cord Blood$1.24B0.09$0.23 per share4.19$6.34 per share0.15LXEOLexeo TherapeuticsN/AN/AN/AN/A$2.95 per shareN/AMRAIMarpai$34.87M0.21N/AN/A($1.72) per share-0.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$287.53M-$1.09N/AN/AN/A-311.98%-109.73%-43.96%N/ACOGlobal Cord Blood$79.04M$0.641.48N/AN/AN/AN/AN/AN/ALXEOLexeo Therapeutics-$99.96M-$1.45N/AN/AN/AN/A-47.48%-41.72%N/AMRAIMarpai-$28.75M-$0.95N/AN/AN/A-85.70%N/A-100.23%N/ALatest CO, MRAI, LXEO, and AUTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026AUTLAutolus Therapeutics-$0.29-$0.27+$0.02-$0.27$26.27 million$26.22 million5/11/2026Q1 2026LXEOLexeo Therapeutics-$0.29-$0.25+$0.04-$0.25N/AN/A3/30/2026Q4 2025LXEOLexeo Therapeutics-$0.32-$0.27+$0.05-$0.27N/AN/A3/27/2026Q4 2025AUTLAutolus Therapeutics-$0.27-$0.34-$0.07-$0.34$23.92 million$24.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ACOGlobal Cord Blood$0.088.42%N/A12.50%N/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/AMRAIMarpaiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A5.945.48COGlobal Cord BloodN/AN/AN/ALXEOLexeo TherapeuticsN/A14.1611.21MRAIMarpaiN/A0.820.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%COGlobal Cord BloodN/ALXEOLexeo Therapeutics60.67%MRAIMarpai49.75%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%COGlobal Cord Blood0.50%LXEOLexeo Therapeutics5.30%MRAIMarpai46.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.74 millionOptionableCOGlobal Cord Blood1,202121.55 millionN/ANo DataLXEOLexeo Therapeutics5878.52 million74.36 millionNot OptionableMRAIMarpai15025.33 million5.61 millionNo DataCO, MRAI, LXEO, and AUTL HeadlinesRecent News About These CompaniesMARPAI REPORTS FIRST QUARTER 2026 FINANCIAL RESULTSMay 15 at 4:03 PM | prnewswire.comMarpai, Inc. Announces Significant New Business Wins across TPA and MarpaiRx; Solidifies Forecast for ProfitabilityMay 11, 2026 | prnewswire.comMarpai (MRAI) Projected to Post Earnings on WednesdayMay 11, 2026 | americanbankingnews.comMarpai Extends Maturity of Insider Promissory NotesMay 1, 2026 | tipranks.comMarpai, Inc. Secures Major Strategic Marketing Collaboration to Continue Acceleration of MarpaiRx Growth NationwideApril 1, 2026 | prnewswire.comMarpai Secures Access to Network Creating Major Growth Catalyst for MarpaiRx Representing Up to 1.5 million Covered LivesMarch 9, 2026 | prnewswire.comMarpai, Inc. Secures Major Strategic Wins for MarpaiRx, Adding Over 19,000 Lives and Accelerating High-Growth Platform ExpansionFebruary 23, 2026 | prnewswire.comMARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTHJanuary 27, 2026 | prnewswire.comMarpai consolidates leadership as CEO Damien Lamendola becomes PresidentJanuary 23, 2026 | tipranks.comMARPAI ANNOUNCES 2026 MOMENTUM AND KEY PARTNERSHIP EXPANSIONDecember 1, 2025 | prnewswire.comMarpai, Inc. Earnings Call Highlights Mixed SentimentNovember 14, 2025 | msn.comMARPAI REPORTS THIRD QUARTER 2025 FINANCIAL RESULTSNovember 12, 2025 | prnewswire.comMarpai Signs Material Definitive AgreementNovember 12, 2025 | tipranks.comMARPAI TO HOST WEBCAST ON NOVEMBER 13, 2025 TO DISCUSS THIRD QUARTER 2025 FINANCIAL RESULTSNovember 6, 2025 | prnewswire.comMarpai Authorizes 2 Million Blank-Check Preferred SharesOctober 21, 2025 | msn.comMarpai Announces Compliance with Securities Exchange ActOctober 19, 2025 | theglobeandmail.comMARPAI RECOGNIZED AS 2025 TOP THIRD PARTY ADMINISTRATOROctober 14, 2025 | prnewswire.comMARPAI, INC. RECEIVES ADDITIONAL $200,000 INVESTMENT FROM DAMIEN LAMENDOLA'S HILLCOUR INVESTMENT FUNDOctober 6, 2025 | prnewswire.comMarpai, Inc. Earnings Call: Mixed Results and Strategic ShiftsAugust 31, 2025 | tipranks.comMarpai Appoints Dallas Scrip as New PresidentAugust 29, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026CO, MRAI, LXEO, and AUTL Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.63 +0.04 (+2.52%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.58 -0.05 (-3.07%) As of 05/15/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Global Cord Blood NYSE:CO$0.95 0.00 (0.00%) As of 05/15/2026Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.Lexeo Therapeutics NASDAQ:LXEO$5.09 -0.41 (-7.45%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$5.18 +0.09 (+1.67%) As of 05/15/2026 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Marpai NASDAQ:MRAI$0.29 -0.02 (-5.35%) As of 05/15/2026 12:53 PM EasternMarpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
